Latest News - Medical - India - Andhra Pradesh - Hyderabad

Dr. Reddy’s has launched Supanac ® (Diclofenac potassium immediate release 50 mg tablets) in India, increasing its offering in the Rs 2700 crores (~ $688 million) NSAID market. (Source: IMS ORG June MAT ’07).

Dr. Reddy’s announces settlement of Exelon (rivastigmine tartrate) ANDA litigation with Novartis

Argenta Discovery Limited, the respiratory drug discovery and development company, and Dr Reddy’s Laboratories (NYSE: RDY), today announce a major milestone in their development programme

-- Agreement with Dr. Reddy’s secures long-term supply to advance the clinical development of SYGNIS’ lead product candidate -- -- Dr. Reddy’s first agreement for the long-term supply of a biological molecule; First of its kind from India --

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited financial results for the quarter ended September 30, 2007.

Dr. Reddy’s Laboratories Limited (NYSE: RDY) announces that the company’s annual report on Form 20-F for the year ended March 31, 2007 is available on its website ( http://www.drreddys.com )

Dr. Reddy's Pharmaceutical Company Commences Operations in Philippines. Expands presence in the ASEAN region

Dr. Reddy’s Laboratories (NYSE:RDY) announced today, that the U.S. Food and Drug Administration (USFDA) has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) for Ranitidine (Zantac™) 150mg tablet.